The pain won't stop. GSK ends the week with a slap­down on its Nu­cala ap­pli­ca­tion for COPD

Glax­o­SmithK­line $GSK just com­plet­ed an un­nec­es­sary and em­bar­rass­ing lap at the FDA with a fresh slap­down.

At a time the com­pa­ny is hop­ing to be­gin to demon­strate that the phar­ma R&D group has be­gun a long-await­ed turn­around, the FDA just com­plet­ed its lat­est hu­mil­i­a­tion on a new ap­pli­ca­tion for Nu­cala with a wide­ly ex­pect­ed com­plete re­sponse let­ter.

In a short state­ment out late Fri­day, the phar­ma gi­ant not­ed:

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.